Journal of Advances and Scholarly Researches in Allied Education
Vol. 22, Issue No. 4, July-2025, ISSN 2230-7540

DOI: https://doi.org/10.29070/6j9hgn17

Check for updates

The Role of Whole-Body MRI in Oncology: Current Status and Future Trends

Lama Khalid Alothaimeen [1] * , Rand Adel Alsowayan [2] , Mohammed Rashed Muteb [3] , Abdulrhman Abdullah S. Alotaibi [4]

1. Radiographer, Prince Sultan Military Medical City, Riyadh, SA
lamakhalidalo@gmail.com ,
2. Radiographer, Prince Sultan Military Medical City, Riyadh, SA ,
3. Radiographer, Prince Sultan Military Medical City, Riyadh, SA ,
4. Radiographer, Prince Sultan Military Medical City, Riyadh, SA

Abstract: Whole-body magnetic resonance imaging (WB-MRI) has emerged as a powerful, non-ionizing modality for the comprehensive assessment of oncologic patients. Its ability to provide a holistic view of the body's soft tissues, bone marrow, and organs in a single examination positions it uniquely for cancer staging, restaging, and screening in high-risk populations. This review delineates the current evidence-based applications of WB-MRI across various malignancies, highlighting its superior sensitivity for bone metastasis detection and its growing role in response assessment. We detail the technical underpinnings of modern WB-MRI protocols, including diffusion-weighted imaging (DWI), which serves as a functional biomarker for tumor cellularity. Furthermore, we explore the burgeoning trends poised to redefine its utility, including the integration of artificial intelligence (AI) for accelerated acquisition and automated analysis, the development of whole-body PET/MRI systems, and the exploration of novel quantitative biomarkers. Despite challenges related to standardization, access, and cost, WB-MRI is increasingly recognized as a cornerstone of precision oncology, offering a safe and comprehensive diagnostic pathway.

Keywords: Whole-Body MRI, Oncology, Diffusion-Weighted Imaging, Cancer Staging, Metastasis, PET/MRI, Artificial Intelligence, Biomarkers

X

INTRODUCTION

The management of cancer is critically dependent on accurate staging at diagnosis and precise assessment of treatment response. For decades, multi-modality approaches combining computed tomography (CT), positron emission tomography (PET)/CT, and bone scintigraphy have been the standard of care. While effective, these strategies involve significant ionizing radiation exposure, which is a particular concern for young patients and those requiring lifelong surveillance. Furthermore, they can lack sensitivity for certain metastases, particularly diffuse bone marrow infiltration or small peritoneal deposits.

Whole-body MRI (WB-MRI) has evolved to address these limitations. Early technical constraints, such as long acquisition times and limited coil coverage, have been largely overcome by advancements in hardware (e.g., multi-channel phased-array coils, high-gradient systems) and software (e.g., parallel imaging, compressed sensing). The incorporation of functional sequences, most notably diffusion-weighted imaging (DWI), has transformed WB-MRI from a purely anatomical tool into a hybrid anatomical-functional modality capable of detecting lesions based on altered water diffusivity.

This paper reviews the current status of WB-MRI in oncology, providing evidence-based insights into its clinical applications. It also projects future trends, including technological innovations and the integration of artificial intelligence, that are set to expand its role further.

TECHNICAL CONSIDERATIONS OF WB-MRI

A modern WB-MRI protocol is not a single sequence but a strategically planned combination of sequences designed to maximize diagnostic yield while minimizing acquisition time.

Core Sequences

T1-weighted Imaging (T1WI): Essential for anatomical delineation, fat characterization (e.g., using Dixon techniques for uniform fat suppression), and detection of bone marrow metastases, which often replace fatty marrow.

T2-weighted Imaging (T2WI) with Fat Suppression (e.g., STIR): Highly sensitive for detecting fluid-filled structures, edema, and most solid tumors, which typically exhibit high T2 signal.

Diffusion-Weighted Imaging (DWI): The functional cornerstone of WB-MRI. It measures the Brownian motion of water molecules. In highly cellular tissues like tumors, water diffusion is restricted, appearing as high signal on high b-value images (e.g., b=800-1000 s/mm²). The corresponding Apparent Diffusion Coefficient (ADC) map provides a quantifiable metric (low ADC values indicate high cellularity)

Protocol Design:

Protocols are tailored to clinical question and hardware but typically involve imaging the body in contiguous stations (e.g., head-neck, chest, abdomen, pelvis, thighs) which are subsequently fused into a seamless whole-body dataset. Automated table movement and integrated surface coils are standard on modern systems.

Table 1: Standard WB-MRI Protocol for Oncologic Staging

Body Station	Sequences	Primary Clinical Utility
Head/Brain	Axial T2 FLAIR, Axial DWI (b=1000), Axial T1	Detect brain metastases, synchronous primaries
Neck	Coronal STIR, Axial T1 Dixon	Evaluate cervical lymph nodes
Chest/Abdomen/Pelvis	Axial T2 Dixon (water-only), Axial T1 Dixon (in/opposed phase), Axial DWI (b=50, b=800-1000), Coronal STIR	Assess primary tumor, thoracic/abdominal lymph nodes, visceral metastases (liver, adrenal), peritoneal disease
Whole Spine	Sagittal T1, Sagittal STIR	Screen for vertebral metastases, cord compression
Whole Body (Fused)	Coronal MIP of STIR and DWI (b=800)	"Snapshot" overview for rapid detection of lymph nodes and bone metastases

CURRENT CLINICAL APPLICATIONS

Metastasis Detection and Staging

WB-MRI excels in detecting metastases, particularly in the bone marrow, where it demonstrates superior sensitivity and specificity compared to CT and bone scintigraphy.

Prostate Cancer: WB-MRI is now a cornerstone in staging high-risk disease, outperforming choline-PET/CT and bone scan for osseous metastases. The PROMIS and STAMPEDE trials have provided high-level evidence supporting its use.

Multiple Myeloma: WB-MRI is the recommended imaging modality by the International Myeloma Working Group for both diagnosis and monitoring. It detects diffuse, focal, and variegated patterns of marrow infiltration unseen by other modalities.

Breast Cancer: While FDG-PET/CT is highly sensitive, WB-MRI is a valuable problem-solving tool and an excellent radiation-free alternative, especially for lobular carcinoma which has a high propensity for peritoneal and osseous metastases.

Other Cancers: Evidence is growing for its use in lymphoma (staging and response), malignant melanoma, and renal cell carcinoma.

Table 2: Performance of WB-MRI vs. Standard Modalities for Bone Metastasis Detection

Primary Cancer	Sensitivity (%) WB-MRI vs. Comparator	Specificity (%) WB-MRI vs. Comparator	Key Comparator
Prostate	95-100% vs. 70-80%	97-100% vs. 95-98%	Bone Scintigraphy
Breast	90-98% vs. 75-85%	95-98% vs. 90-95%	FDG-PET/CT / Bone Scan
Multiple Myeloma	95-100% vs. 70-80%	90-95% vs. 80-90%	Skeletal Survey / Low-Dose CT

Cancer Screening in High-Risk Populations

WB-MRI is the modality of choice for screening individuals with genetic cancer predisposition syndromes due to the absence of radiation.

Li-Fraumeni Syndrome (TP53 mutation): Annual WB-MRI is recommended and has been shown to improve survival through early detection of a wide range of malignancies.

Hereditary Paraganglioma-Pheochromocytoma Syndromes (e.g., SDHx mutations): WB-MRI with DWI is highly effective for detecting primary and metastatic lesions.

Other Syndromes: It is also used in surveillance for BRCA1/2 carriers (for other cancers beyond breast/ovary) and other high-risk scenarios.

Treatment Response Assessment

Functional information from DWI allows for early assessment of treatment efficacy. A successful response often leads to cell death and reduced cellularity, manifesting as an increase in the ADC value before a morphological change in tumor size is apparent (functional response). This is particularly useful in assessing response in bone metastases, where changes on CT are slow and sclerotic reactions can be mistaken for progression.

ADVANTAGES AND LIMITATIONS

Advantages:

No Ionizing Radiation: Permits safe repeated examinations for surveillance.

Superior Soft-Tissue Contrast: Excellent for visualizing the bone marrow, liver, and brain.

Functional Information: DWI provides unique insights into tumor cellularity and treatment response.

Comprehensive "One-Stop-Shop" Exam: Single examination from head to toe.

Limitations:

Longer Acquisition Times: Typically 45-60 minutes vs. 15-20 for PET/CT.

Claustrophobia and Contraindications: Not suitable for patients with certain implants (e.g., non-MRI compatible pacemakers) or severe claustrophobia.

Limited Lung Nodule Detection: While improving, CT remains superior for characterizing sub-centimeter lung nodules.

Cost and Accessibility: Higher upfront cost of MRI systems and limited scanner availability in some regions.

Reader Expertise and Standardization: Interpretation requires specialized training, and lack of universally accepted reporting criteria (like PERCIST for PET or RECIST for CT) can hinder widespread adoption

FUTURE TRENDS

Integration of Artificial Intelligence (AI)

AI is set to revolutionize WB-MRI in two key areas:

1. **Acquisition:** Deep learning-based reconstruction algorithms (e.g., AIR Recon DL, Compressed Sensing) can dramatically reduce scan times by acquiring less data and synthetically filling in the gaps, making WB-MRI faster and more comfortable.

2. **Interpretation:** AI algorithms can automate tedious tasks like bone lesion segmentation, lymph node detection, and liver metastasis volumetry. This can reduce reading time, minimize observer variability, and extract quantitative data beyond human perception.

Hybrid PET/MRI Systems

Whole-body PET/MRI scanners combine the exquisite soft-tissue and functional detail of MRI with the high sensitivity and metabolic profiling of PET. This fusion creates a supremely powerful tool for characterizing complex tumors (e.g., assessing tumor heterogeneity, differentiating recurrence from treatment effect) and guiding biopsy. While currently limited by cost and complexity, it represents the pinnacle of hybrid imaging.

Advanced Quantitative Biomarkers

Beyond ADC, research is focused on extracting more sophisticated biomarkers from WB-MRI data:

Intravoxel Incoherent Motion (IVIM): Separates microcapillary perfusion from true diffusion.

Texture Analysis: Extracts data on spatial heterogeneity of signal intensity within a tumor, which may correlate with tumor genomics and aggressiveness.

Whole-Body Radiomics: The high-throughput extraction of vast quantitative features from the entire WB-MRI dataset to build predictive models for outcomes and treatment response.

Table 3: Emerging Quantitative Biomarkers in WB-MRI

Biomarker	Sequence Source	Biological Correlate	Potential Clinical Application
ADC (Standard)	DWI	Tumor Cellularity	Treatment response monitoring
IVIM (D, f, D)	Multi-b-value DWI	Perfusion (f, D) & Diffusion (D)	Differentiating true diffusion change from perfusion effects post-therapy
Texture Features	T1, T2, DWI	Tumor Heterogeneity	Predicting tumor grade, mutation status (e.g., in gliomas), prognosis
Magnetic Resonance Spectroscopy (MRS)	Dedicated MRS	Tissue Metabolite Levels (e.g., choline)	Characterizing prostate cancer aggressiveness

CONCLUSION

Whole-body MRI has firmly established itself as an indispensable tool in the modern oncologic imaging arsenal. Its lack of radiation, unparalleled sensitivity for bone marrow disease, and unique functional capabilities provided by DWI make it the preferred modality for specific cancers like prostate cancer and multiple myeloma, and for screening high-risk genetic populations.

The future of WB-MRI is exceptionally bright, driven by technological convergence. The integration of AI will streamline workflows and unlock deeper quantitative insights from imaging data. The synergy of PET/MRI promises a truly comprehensive metabolic and morphologic evaluation. As these technologies mature and become more accessible, WB-MRI is poised to transition from a specialized technique to a mainstream pillar of precision cancer care, enabling earlier detection, more accurate staging, and personalized response assessment.

References

1. PROMIS Study Group. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815-822.
2. Sala, E., & (2020). The role of whole-body MRI in the diagnosis and management of prostate cancer. BJU International, 126(S1), 15-17. (Commentary on STAMPEDE trial data integration).
3. Giles, S. L., et al. (2019). Whole-body MRI for initial staging of patients with breast cancer: a systematic review and meta-analysis. European Radiology, 29(9), 4744-4757.
4. Lecouvet, F. E., et al. (2018). Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? European Urology, 74(1), 17-24.
5. Messiou, C., et al. (2019). Prospective evaluation of whole-body MRI versus FDG PET/CT for lesion detection in participants with myeloma. Radiology, 293(2), 464-474.
6. Ballinger, M. L., et al. (2017). Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncology, 3(12), 1634-1639.
7. Padhani, A. R., et al. (2020). METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. European Urology, 77(1), 81-92.
8. Messiou, C., et al. (2021). Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology, 299(1), 161-170.
9. Kuhl, C. K., et al. (2022). European Society of Breast Imaging (EUSOBI) recommendations on the use of breast MRI for supplemental screening of women with dense breasts and at intermediate risk.

European Radiology, 32(6), 4036-4045. (Includes discussion on WB-MRI in high-risk genetic scenarios).

10. Expert Panel on MR Safety., et al. (2020). ACR guidance document on MR safe practices:2020. Journal of Magnetic Resonance Imaging, 51(2), 331-338.
11. Schmidt, G. P., & Kramer, H. (2017). Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Topics in Magnetic Resonance Imaging, 26(1), 19-25.
12. Kwee, T. C., & Kwee, R. M. (2019). Whole-body MRI for staging and follow-up of oncology patients. European Journal of Radiology, 118, 128-135.
13. Petralia, G., et al. (2019). Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. La Radiologia Medica, 124(3), 218-233.
14. Takahara, T., et al. (2004). Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution3D display. Radiation Medicine, 22(4), 275-282. (Seminal paper on DWIBS technique).
15. Mayerhoefer, M. E., et al. (2020). Introduction to Radiomics. Journal of Nuclear Medicine, 61(4), 488-495.
16. Lemasson, B., et al. (2021). MR-based radiomics and machine learning for the assessment of prostate cancer aggressiveness: a systematic review and meta-analysis. European Radiology, 31(9), 6476-6487.
17. Gatidis, S., et al. (2021). The role of AI in whole-body MRI for oncologic patients. Investigative Radiology, 56(7), 447-455.
18. Bickelhaupt, S., et al. (2018). Radiomics based on adapted diffusion kurtosis imaging helps to clarify most mammographic findings suspicious for cancer. Radiology, 287(3), 761-770.
19. Boss, A., et al. (2010). Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. Journal of Nuclear Medicine, 51(8), 1198-1205.
20. Donati, O. F., et al. (2014). Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. Journal of Nuclear Medicine, 55(1), 54-59.
21. Zhao, J., et al. (2021). Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology: Imaging Cancer, 3(3), e200120.
22. Costa, L. B., et al. (2021). The role of imaging in multiple myeloma. American Society of Clinical Oncology Educational Book, 41, e1-e17.
23. Eisenhauer, E. A., et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer, 45(2), 228-247. (Critical for understanding the standard against which functional WB-MRI is often compared).

24. Wahl, R. L., et al. (2009). From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. Journal of Nuclear Medicine, 50(Suppl 1), 122S-150S. (Provides context for functional/metabolic response assessment).

25. Padhani, A. R., et al. (2020). "METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer." European Urology, 77(1), 81-92.

26. Messiou, C., et al. (2021). "Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)." Radiology, 299(1), 161-170.

27. Petralia, G., et al. (2019). "Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses." La Radiologia Medica, 124(3), 218-233.

28. Kwee, T. C., & Kwee, R. M. (2019). "Whole-body MRI for staging and follow-up of oncology patients." European Journal of Radiology, 118, 128-135.

29. Ballinger, M. L., et al. (2017). "Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis." JAMA Oncology, 3(12), 1634-1639.

30. Mayerhoefer, M. E., et al. (2020). "Introduction to Radiomics." Journal of Nuclear Medicine, 61(4), 488-495